Chemotherapy of advanced soft-tissue sarcomas in adults

Pinedo, Herbert H.M.; Kenis, Yvon

doi:10.1016/s0305-7372(77)80006-6

Cited by 121 publications

(26 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[27][28][29] However, no investigator has reported the role of adjuvant chemotherapy in treatment of primary intradural MPNST. It was reported that the most common sites for metastatic spread after removal of intradural MPNSTs were the lungs and liver in patients not treated by chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Primary malignant peripheral nerve sheath tumor of the cauda equina in a child case report

Yone¹,

Ijiri²,

Hayashi³

et al. 2004

Spinal Cord

View full text Add to dashboard Cite

Study design: A case report of primary malignant peripheral nerve sheath tumor (MPNST) of the cauda equina in a child is presented, and the literature is reviewed. Objective: To discuss the problems involved in the treatment of primary intradural MPNSTs. Setting: A department of orthopaedic surgery in Japan. Methods: A 4-year-old boy complained of low-back pain radiating to the left calf. MRI revealed an intradural tumor at L3-L5 level. Following laminectomy of L3, L4 and L5, the tumor was removed en bloc. Based on pathological and immunohistological findings, the tumor was diagnosed as an MPNST. Results: Although adjuvant chemotherapy was administered local recurrence and cerebral and spinal metastases of the tumor were found 6 months after the operation. Following additional incomplete removal of the recurrent tumor, radiation therapy was administered. Although recurrent and metastatic tumors disappeared or diminished in size by radiation, tumors increased in size thereafter, despite additional adjuvant chemotherapy. At 21 months after the first operation, he died of pneumonia. Conclusions: Reported clinical outcomes for patients with primary intradural MPNST are very poor. Although no gold standard for the treatment of tumors has been established yet, surgical removal of tumors combined with postoperative high-dose radiation may be recommended.

show abstract

Section: Discussionmentioning

confidence: 99%

Primary malignant peripheral nerve sheath tumor of the cauda equina in a child case report

Yone¹,

Ijiri²,

Hayashi³

et al. 2004

Spinal Cord

View full text Add to dashboard Cite

show abstract

“…In recent years, it has been shown that several drugs are effective in advanced soft tissue sarcoma [24][25][26]. The most potent drugs in adults are adriamycin [27], and DTIC [27][28][29], but cyclophosphamide [30,31] probably has some activity (Table 3).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of adjuvant therapy in soft tissue sarcoma. A collaborative multidisciplinary approach

Pinedo¹,

Vendrik²,

Bramwell³

et al. 1979

European Journal of Cancer (1965)

Self Cite

View full text Add to dashboard Cite

“…These include doxorubicin, ifosfamide and dacarbazine. Doxorubicin and ifosfamide are considered the cornerstones of treatment for advanced STS, consistently producing responses as monotherapy in more than 20% of previously untreated patients (Pinedo and Kenis, 1977). Most studies have demonstrated a clear doseresponse relationship for both of these drugs (O'Bryan et al, 1977, Antman et al, 1990.…”

mentioning

confidence: 99%

Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group

et al. 2004

View full text Add to dashboard Cite

Patients with soft tissue sarcoma (STS), even after complete local disease control, often relapse locally or with distant metastases. This multicenter phase II study was conducted to evaluate the safety and efficacy of the combination of pegylated liposomal doxorubicin (PLD) and paclitaxel, as first-line treatment in patients with advanced STS. In all, 42 patients with locally advanced or metastatic STS, median age 54 years and median Eastern Cooperative Oncology Group performance status (PS) 1 were treated with PLD 45 mg m À2 and paclitaxel 150 mg m À2 , every 28 days for a total of six cycles. Histological types included mainly leiomyosarcomas (43%), malignant fibrous histiocytomas (14%) and liposarcomas (12%). At study entry, 69% of patients had distant metastases. Overall response rate was 16%, including one complete (CR 2%) and six partial responses (PRs 14%), while an additional 14 patients had disease stabilization (SD 33%). At median follow-up 41.5 months, median time to progression (TTP) was 5.7 months with median overall survival (OS) 13.2 months. Grade 3 -4 toxicities included neutropenia (17%), anaemia (15%), neurotoxicity (5%) and palmarplantar erythrodysesthesia (9%). There were no treatment-related deaths. The combination of PLD and paclitaxel is a safe and welltolerated regimen demonstrating modest efficacy as first-line treatment in patients with advanced STS.

show abstract

Chemotherapy of advanced soft-tissue sarcomas in adults

Cited by 121 publications

References 54 publications

Primary malignant peripheral nerve sheath tumor of the cauda equina in a child case report

Primary malignant peripheral nerve sheath tumor of the cauda equina in a child case report

Evaluation of adjuvant therapy in soft tissue sarcoma. A collaborative multidisciplinary approach

Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group

Contact Info

Product

Resources

About